- We will send in 10–14 business days.
/images/books/12470145/9781907673931.jpg)
- Author: Ricardo H Alvarez
- Publisher: Springer Healthcare
- ISBN-10: 1907673938
- ISBN-13: 9781907673931
- Format: 12.7 x 19.8 x 0.8 cm, minkšti viršeliai
- Language: English
- SAVE -10% with code: EXTRA
Handbook of Her2-Targeted Agents in Breast Cancer (e-book) (used book) | bookbook.eu
Reviews
Description
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15-25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 23d.00:15:24
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Author: Ricardo H Alvarez
- Publisher: Springer Healthcare
- ISBN-10: 1907673938
- ISBN-13: 9781907673931
- Format: 12.7 x 19.8 x 0.8 cm, minkšti viršeliai
- Language: English English
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15-25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.
Reviews